SAFETY AND EFFICACY OF MK-906 IN PATIENTS WITH BENIGN PROSTATIC HYPERTROPHY

MK-906 在良性前列腺肥大患者中的安全性和有效性

• 批准号: 3866018
• 负责人: MARGUERITE C LIPPERT
• 金额: --
• 依托单位: UNIVERSITY OF VIRGINIA
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/3866018
• 关键词: benign prostate hyperplasia; clinical trials; dihydrotestosterone; drug adverse effect; drug tolerance; human subject; human therapy evaluation; hypothalamic pituitary axis; oxidoreductase inhibitor; pituitary gonadal axis; placebos; reproductive system disorder chemotherapy; testis

Double-blind, placebo-controlled, randomized multicenter study to investigate the safety, tolerability, and efficacy of MK-906 in patients with benign prostatic hypertrophy. MK-906 is a 5-alpha reductase inhibitor, which will allow us to assess the effect of 5-alpha DHT on the hypothalomo-pituitary testicular axis.

双盲、安慰剂对照、随机化、多中心研究， 研究MK-906在患者中的安全性、耐受性和疗效 良性前列腺肥大 MK-906是一种5-α还原酶 抑制剂，这将使我们能够评估5-α DHT对 下丘脑-垂体睾丸轴